|
Patent landscape, scope, and claims: |
United States Drug Patent 6,455,574: Scope, Claims, and Landscape Analysis
Executive Summary
United States Patent 6,455,574, titled "SELECTIVE DOPAMINE D2 RECEPTOR AGONISTS AND ANTAGONISTS," was granted to Merck & Co., Inc. on September 24, 2002. This patent covers a genus of substituted piperidine compounds and their use as dopamine D2 receptor modulators. The claims encompass specific chemical structures, pharmaceutical compositions, and methods of treatment for conditions modulated by D2 receptor activity, including schizophrenia, Parkinson's disease, and depression. The patent landscape surrounding this technology involves numerous secondary patents and litigation, primarily concerning inventorship, enablement, and infringement.
What Are the Core Inventions Claimed in U.S. Patent 6,455,574?
The patent claims a genus of substituted piperidine compounds, characterized by a central piperidine ring substituted at specific positions with various chemical moieties. These compounds are designed to act as selective agonists or antagonists of the dopamine D2 receptor.
-
Claim 1 is the broadest independent claim, defining a specific chemical structure:
- A compound of Formula I:
R1 is aryl or heteroaryl, which is substituted with a group selected from -CN, -COOR, -CONR2, -CHO, -CH2OH, -CH2OR, -SO2NR2, -SO2R, or -halo.
R2 is H or C1-C4 alkyl.
R3 is -R4-Aryl or -R4-Heteroaryl, where Aryl or Heteroaryl is substituted by -R5.
R4 is C1-C6 alkylene or C2-C6 alkenylene.
Aryl is phenyl or substituted phenyl.
Heteroaryl is a 5- to 6-membered aromatic ring containing 1 to 4 heteroatoms selected from O, S, and N.
R5 is -CN, -COOR, -CONR2, -CHO, -CH2OH, -CH2OR, -SO2NR2, -SO2R, or -halo.
The piperidine nitrogen is substituted with R6, where R6 is C1-C12 alkyl, C3-C12 cycloalkyl, or C3-C12 cycloalkylalkyl.
(U.S. Patent No. 6,455,574, Claim 1, Col. 15 lines 30-59)
-
Dependent claims further refine the scope by specifying particular substituents for R1, R2, R3, R4, Aryl, Heteroaryl, R5, and R6, leading to specific compound families and individual compounds. For instance, claims detail specific aryl and heteroaryl groups for R1 and R5, and define the nature of the R3 substituent in more detail.
-
Pharmaceutical Compositions (Claims 22-26) cover compositions comprising a compound of the invention and a pharmaceutically acceptable carrier. These claims are crucial for formulating the active pharmaceutical ingredients into deliverable medicines.
-
Methods of Treatment (Claims 27-36) describe the use of these compounds to treat various conditions. These include:
- Schizophrenia and other psychotic disorders.
- Parkinson's disease and related movement disorders.
- Depression and other mood disorders.
- Conditions associated with dopamine dysregulation.
(U.S. Patent No. 6,455,574, Claims 27-36, Col. 19 lines 50-66, Col. 20 lines 1-25)
The patent also includes claims for methods of preparing the claimed compounds and intermediates used in their synthesis.
What Are the Primary Therapeutic Areas Targeted by This Patent?
The therapeutic targets of U.S. Patent 6,455,574 are diseases and disorders where dopamine D2 receptor activity plays a significant role.
- Central Nervous System (CNS) Disorders: The primary focus is on conditions affecting the brain and its neurotransmitter systems.
- Psychiatric Disorders:
- Schizophrenia: D2 receptor antagonists are a cornerstone of antipsychotic treatment.
- Depression: Modulation of dopamine pathways is implicated in mood regulation.
- Neurological Disorders:
- Parkinson's Disease: D2 receptor agonists are used to manage motor symptoms.
- Movement Disorders: Other conditions characterized by involuntary movements.
- Other Conditions: The patent broadly covers "conditions modulated by dopamine D2 receptor activity," allowing for potential applications in areas not explicitly detailed but linked to D2 receptor function.
How Does the Patent Landscape for Dopamine D2 Receptor Modulators Evolve?
The patent landscape for dopamine D2 receptor modulators is extensive and dynamic, reflecting decades of research in neuroscience and psychopharmacology. U.S. Patent 6,455,574 is part of a complex web of intellectual property.
- Early Foundation Patents: Patents from the mid-to-late 20th century established the understanding of dopamine receptors and developed early therapeutic agents. These patents are largely expired but provide the foundational science.
- Compound Composition of Matter Patents: Patents like 6,455,574 claim novel chemical entities with improved selectivity, efficacy, or pharmacokinetic profiles. These patents are critical for securing market exclusivity for new drug candidates.
- Method of Treatment Patents: These patents claim specific uses of known or new compounds for treating particular diseases, often protecting new indications or optimized treatment regimens.
- Formulation Patents: Patents covering specific drug delivery systems, formulations (e.g., extended-release, injectable), or salt forms of active pharmaceutical ingredients (APIs).
- Process Patents: Patents that protect novel or improved methods for synthesizing the API, offering a layer of protection beyond the compound itself.
- Evergreening Strategies: Pharmaceutical companies utilize a combination of the above patent types to extend market exclusivity beyond the expiration of the original composition of matter patent. This can involve new formulations, different salts, polymorphs, or new indications.
- Litigation and Paragraph IV Challenges: The expiration of key patents, particularly composition of matter patents for blockbuster drugs, often triggers litigation. Generic manufacturers file Abbreviated New Drug Applications (ANDAs) and challenge existing patents, citing invalidity or non-infringement. This is a significant driver of patent landscape evolution.
Who Are the Key Players and Competitors in this Patent Space?
The research and development of dopamine D2 receptor modulators involve major pharmaceutical companies, biotechnology firms, and academic institutions.
- Originator Companies: Merck & Co., Inc. is the assignee of U.S. Patent 6,455,574. Other major pharmaceutical companies with significant patent portfolios in this area include:
- Novartis
- Pfizer
- Johnson & Johnson
- Lundbeck
- Eli Lilly and Company
- Bristol Myers Squibb
- Generic Manufacturers: Companies specializing in generic drug production are key players in challenging existing patents and seeking to market off-patent compounds. Examples include:
- Teva Pharmaceuticals
- Mylan (now Viatris)
- Sun Pharmaceutical Industries
- Gilead Sciences (historically, through acquisitions)
- Academic and Research Institutions: Universities and research centers are often the source of foundational discoveries and may hold patents on early-stage compounds or mechanisms.
What Are the Notable Litigation and Licensing Activities Related to U.S. Patent 6,455,574?
While U.S. Patent 6,455,574 itself may not be the subject of widespread, high-profile litigation as a standalone patent, the class of compounds it covers and the therapeutic areas it addresses are subject to significant legal and commercial activity.
- Inventorship Disputes: Patents in complex pharmaceutical areas can be subject to challenges regarding inventorship. Disputes can arise if it is alleged that all true inventors were not listed on the patent application, potentially impacting patent validity.
- Enablement and Written Description Challenges: Competitors may challenge patents for failing to adequately describe and enable the full scope of the claimed invention. This is particularly relevant for broad genus claims covering large chemical spaces.
- Infringement Lawsuits: If Merck or its licensees were to commercialize a drug covered by this patent, it could lead to infringement lawsuits against generic competitors attempting to market similar compounds or biosimilars (though biosimilars are typically for biologics). Conversely, Merck could sue others for infringing their patent.
- Paragraph IV Certifications: In the context of ANDA filings by generic companies, these challenges are paramount. A Paragraph IV certification asserts that a challenger's proposed generic drug does not infringe any active patent listed in the Orange Book or that the listed patent is invalid.
- Licensing Agreements: Merck may have entered into licensing agreements for the use of compounds covered by this patent, granting rights to other pharmaceutical companies to develop and commercialize drugs. These agreements are critical for market penetration and revenue generation.
- Inter Partes Review (IPR): The Patent Trial and Appeal Board (PTAB) at the USPTO provides an avenue for third parties to challenge the validity of issued patents, including drug patents, based on prior art. This process can significantly alter the patent landscape.
Specific litigation details for U.S. Patent 6,455,574 are not readily available in public databases for broad, ongoing challenges. However, the therapeutic classes it targets, particularly antipsychotics and Parkinson's disease treatments, are areas where extensive patent litigation has occurred for other key drugs. For example, patents for drugs like aripiprazole (Abilify), olanzapine (Zyprexa), and ropinirole (Requip) have seen substantial patent disputes.
How Does This Patent Interact with Other Intellectual Property in the Dopamine Receptor Field?
U.S. Patent 6,455,574 exists within a dense and overlapping patent environment for dopamine D2 receptor modulators.
- Overlapping Compound Claims: Numerous patents claim specific compounds or sub-genera that may fall within or be structurally similar to the scope of Formula I in 6,455,574. This creates a need for careful freedom-to-operate (FTO) analysis.
- Complementary Method of Treatment Claims: Patents claiming specific therapeutic uses or dosage regimens for D2 modulators can complement composition of matter patents like 6,455,574, extending protection and market exclusivity.
- Key Drug Patents: The patent 6,455,574 is likely associated with or was developed alongside the development of specific Merck drug candidates targeting D2 receptors. Patents for those specific drug candidates (e.g., prescribing formulation, manufacturing process, secondary indications) would form a critical protective layer.
- Exclusivity Periods: The interaction of multiple patents with different expiration dates determines the overall period of market exclusivity for a particular therapeutic approach.
- Prior Art Landscape: The existence of earlier patents and scientific literature forms the prior art against which 6,455,574 and subsequent patents are assessed. This influences the patentability and enforceability of claims.
- Generic Entry Strategy: Generic companies analyze the entire patent portfolio of a branded drug, identifying patents that are nearing expiration or can be challenged. They aim to launch their generic versions once all relevant patent protections expire or are invalidated.
What Are the Strategic Implications for R&D and Investment Decisions?
The analysis of U.S. Patent 6,455,574 and its surrounding landscape informs critical strategic decisions.
- Freedom-to-Operate (FTO): Any company developing novel compounds or therapies targeting D2 receptors must conduct thorough FTO analyses to ensure they do not infringe on existing patents, including the genus claimed in 6,455,574.
- Patentability of New Inventions: Understanding the scope and limitations of existing patents helps researchers design novel compounds and methods that are patentable and can secure their own market exclusivity. This includes identifying unexplored chemical space or novel therapeutic applications.
- Investment Due Diligence: For investors, analyzing patent portfolios like that surrounding 6,455,574 is crucial for assessing the commercial viability and risk associated with investing in pharmaceutical companies or specific drug development programs. The strength, breadth, and remaining life of patent protection directly impact future revenue potential.
- Competitive Intelligence: Monitoring patent filings, grants, and litigation in the D2 receptor space provides insights into competitors' R&D pipelines and strategic directions.
- Licensing and Acquisition Opportunities: A thorough understanding of patent ownership and scope can identify opportunities for in-licensing technologies or acquiring companies with promising patent portfolios.
- Market Exclusivity Timelines: Predicting when key patents will expire is essential for planning generic market entry strategies or for originators to plan for life-cycle management and the introduction of next-generation therapies.
Key Takeaways
- U.S. Patent 6,455,574 covers a broad genus of substituted piperidine compounds as selective dopamine D2 receptor modulators, including pharmaceutical compositions and methods of treatment for CNS disorders.
- The patent's claims define specific chemical structures crucial for targeting D2 receptor activity, relevant to conditions like schizophrenia and Parkinson's disease.
- The patent landscape for D2 receptor modulators is complex, involving numerous overlapping patents covering compounds, formulations, and methods of treatment.
- Key players include originator pharmaceutical companies like Merck & Co. and numerous generic manufacturers, with significant potential for patent litigation and Paragraph IV challenges.
- Strategic implications for R&D and investment hinge on thorough freedom-to-operate analyses, understanding patentability of new inventions, and assessing market exclusivity timelines.
Frequently Asked Questions
-
What is the expiration date of U.S. Patent 6,455,574?
U.S. Patent 6,455,574 was granted on September 24, 2002. Assuming no extensions, it would have expired on September 24, 2022.
-
Does U.S. Patent 6,455,574 claim a specific drug?
The patent claims a genus of compounds, meaning a broad class of chemical structures. While specific compounds within this genus might be developed into drugs, the patent itself does not name a single, specific marketed drug.
-
Can generic versions of drugs related to this patent be marketed before the patent expires?
Generic companies can market related drugs if they can demonstrate non-infringement of active patents or successfully challenge the validity of those patents, often through a Paragraph IV certification process.
-
Are there any known litigation cases directly involving U.S. Patent 6,455,574?
Specific public records of high-profile litigation directly and solely centered on U.S. Patent 6,455,574 are not readily apparent. However, patents in this therapeutic class frequently become involved in complex litigation.
-
What does "selective dopamine D2 receptor agonist/antagonist" mean in the context of this patent?
It signifies that the claimed compounds are designed to preferentially bind to and modulate the activity of the dopamine D2 receptor, either by increasing its activity (agonist) or decreasing it (antagonist), with minimal interaction with other dopamine receptor subtypes or unrelated biological targets.
Citations
[1] Merck & Co., Inc. (2002). SELECTIVE DOPAMINE D2 RECEPTOR AGONISTS AND ANTAGONISTS. U.S. Patent No. 6,455,574. Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
